Projects
Dual targeting of CCr2 and CCR5 as thearpy for hepatocellular carcinoma: can we break immune tolerance? Ghent University
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide for which, in case of advanced disease, the current standard therapy has limited survival benefit. HCC is an inlammation-related cancer and the link between chronic inflammation and tumour development and progression provides a promising target for the development of new HCC therapy. During advanced HCC, there is a state of unresponsiveness of the ...
Immunopathogenesis of the immune reconstitution inflammatory syndrome (IRIS) in TB/HIV patients commencing antiretroviral therapy: search for prognostic and diagnostic markers. University of Antwerp
Immunopathogenesis of the immune reconstitution inflammatory syndrome (IRIS) in TB/HIV patients commencing antiretroviral therapy: search for prognostic and diagnostic markers. University of Antwerp
Combining immune stimulation with inhibition of immune suppression to boost innate immunity in cancer. University of Antwerp
Understanding non-genetic processes remodelling the tumor ecosystem, cancer cell death and immune escape mechanisms KU Leuven
Efficient tumor clearance by anticancer therapies requires effective therapy-mediated debulking along with the engagement of the immune system. The induction of regulated cancer cell death (RCD) able to reinstate, rather than suppressing, anticancer immune responses -so called immunogenic cell death - is therefore a highly desirable therapeutic effect. However, the recognition and clearance of residual cancer cells by the immune system, ...
The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets. University of Antwerp
Development of a bispecific immunotracer against CD8 and CD69 for enhanced non-invasive imaging of immune responses during anti-cancer immunotherapy Vrije Universiteit Brussel
recognize and kill malignant tumor cells. Many types of immunotherapies have been developed with
generally favorable outcomes. However, not all patients benefit, and side effects vary greatly. Thus,
there is an unmet need for a personalized approach.
Currently, blood and tissue biomarkers are used to assess the patient's ...